Ki-67 protein as a tumour proliferation marker.

[1]  Y. Homma,et al.  Diagnostic utility of Ki-67 immunohistochemistry in small endoscopic biopsies of the ureter and renal pelvis. , 2017, Pathology, research and practice.

[2]  J. Joo,et al.  The prognostic value of BAP1, PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue markers in localized renal cell carcinoma: A retrospective study of tissue microarrays using immunohistochemistry , 2017, PloS one.

[3]  J. Colinge,et al.  Cell-Cycle Regulation Accounts for Variability in Ki-67 Expression Levels. , 2017, Cancer research.

[4]  Hong-zhao Li,et al.  Prognostic and clinicopathological role of high Ki-67 expression in patients with renal cell carcinoma: a systematic review and meta-analysis , 2017, Scientific Reports.

[5]  N. Naseem,et al.  MCM - 2 and Ki - 67 as proliferation markers in renal cell carcinoma: A quantitative and semi - quantitative analysis , 2016, International braz j urol : official journal of the Brazilian Society of Urology.

[6]  Anthony A. Hyman,et al.  Ki-67 acts as a biological surfactant to disperse mitotic chromosomes , 2016, Nature.

[7]  Yi-huan Luo,et al.  High Ki-67 Immunohistochemical Reactivity Correlates With Poor Prognosis in Bladder Carcinoma , 2016, Medicine.

[8]  Philippe Jay,et al.  The cell proliferation antigen Ki-67 organises heterochromatin , 2016, eLife.

[9]  O. Krishna,et al.  Immunohistochemical Expression of Ki67 and p53 in Wilms Tumor and Its Relationship with Tumor Histology and Stage at Presentation , 2016, Pathology research international.

[10]  Minfeng Chen,et al.  The Prognostic Role of Ki-67/MIB-1 in Upper Urinary-Tract Urothelial Carcinomas: A Systematic Review and Meta-Analysis. , 2015, Journal of endourology.

[11]  S. Barni,et al.  Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients , 2015, Breast Cancer Research and Treatment.

[12]  Wei Zhou,et al.  Ki-67 as a prognostic marker in early-stage non-small cell lung cancer in Asian patients: a meta-analysis of published studies involving 32 studies , 2015, BMC Cancer.

[13]  W. V. van Roon-Mom,et al.  Antisense oligonucleotides in therapy for neurodegenerative disorders. , 2015, Advanced drug delivery reviews.

[14]  Gang Chen,et al.  The Prognostic Role of Ki-67/MIB-1 in Cervical Cancer: A Systematic Review with Meta-Analysis , 2015, Medical science monitor : international medical journal of experimental and clinical research.

[15]  M. Takagi,et al.  Ki67 Antigen Contributes to the Timely Accumulation of Protein Phosphatase 1γ on Anaphase Chromosomes* , 2014, The Journal of Biological Chemistry.

[16]  C. Ponting,et al.  Ki-67 is a PP1-interacting protein that organises the mitotic chromosome periphery , 2014, eLife.

[17]  Gorelov Ai,et al.  [Prognostic value of ki-67 and vimentin markers in patients with metastatic kidney cancer]. , 2014 .

[18]  Y. Lotan,et al.  Ki67 is an independent predictor of oncological outcomes in patients with localized clear‐cell renal cell carcinoma , 2014, BJU international.

[19]  Xin He,et al.  Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis , 2014, BMC Cancer.

[20]  J. Benoit,et al.  A review of the current status of siRNA nanomedicines in the treatment of cancer. , 2013, Biomaterials.

[21]  Jie Yang,et al.  Effects of G250 promoter controlled conditionally replicative adenovirus expressing Ki67‐siRNA on renal cancer cell , 2012, Cancer science.

[22]  Junnian Zheng,et al.  Analysis of human Ki-67 gene promoter and identification of the Sp1 binding sites for Ki-67 transcription , 2012, Tumor Biology.

[23]  Carlos Caldas,et al.  A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER‐positive breast cancer , 2012, The Journal of pathology.

[24]  Junnian Zheng,et al.  p53 regulates Ki-67 promoter activity through p53- and Sp1-dependent manner in HeLa cells , 2011, Tumor Biology.

[25]  Junnian Zheng,et al.  A critical role of Sp1 transcription factor in regulating the human Ki-67 gene expression , 2011, Tumor Biology.

[26]  W. Jonat,et al.  Is the Ki-67 labelling index ready for clinical use? , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  Wong-Ho Chow,et al.  Epidemiology and risk factors for kidney cancer , 2010, Nature Reviews Urology.

[28]  I. Vernos,et al.  The Role of Hklp2 in the Stabilization and Maintenance of Spindle Bipolarity , 2009, Current Biology.

[29]  P. Kaldis,et al.  Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms , 2009, Oncogene.

[30]  C. Lohse,et al.  Development and evaluation of BioScore , 2009, Cancer.

[31]  M. Čemažar,et al.  Evaluation of shRNA-mediated gene silencing by electroporation in LPB fibrosarcoma cells , 2008 .

[32]  G Hüttmann,et al.  Chromophore‐assisted light inactivation of pKi‐67 leads to inhibition of ribosomal RNA synthesis , 2007, Cell proliferation.

[33]  T. Vahlberg,et al.  The association of immunoreactive p53 and Ki-67 with T-stage, grade, occurrence of metastases and survival in renal cell carcinoma. , 2006, Anticancer research.

[34]  Junnian Zheng,et al.  Treatment with vector-expressed small hairpin RNAs against Ki67 RNA-induced cell growth inhibition and apoptosis in human renal carcinoma cells. , 2006, Acta biochimica et biophysica Sinica.

[35]  Gavin D. Grant,et al.  Common markers of proliferation , 2006, Nature Reviews Cancer.

[36]  Junnian Zheng,et al.  Knockdown of Ki-67 by small interfering RNA leads to inhibition of proliferation and induction of apoptosis in human renal carcinoma cells. , 2006, Life sciences.

[37]  Mitch Dowsett,et al.  Proliferation marker Ki-67 in early breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  M. Takagi,et al.  In vivo dynamics and kinetics of pKi-67: transition from a mobile to an immobile form at the onset of anaphase. , 2005, Experimental cell research.

[39]  K. Stoeber,et al.  Mcm2, Geminin, and KI67 Define Proliferative State and are Prognostic Markers in Renal Cell Carcinoma , 2005, Clinical Cancer Research.

[40]  Junnian Zheng,et al.  Anti-Ki-67 peptide nucleic acid affects the proliferation and apoptosis of human renal carcinoma cells in vitro. , 2005, Life sciences.

[41]  G. Sczakiel,et al.  Inhibition of Ki‐67 in a renal cell carcinoma severe combined immunodeficiency disease mouse model is associated with induction of apoptosis and tumour growth inhibition , 2005, BJU international.

[42]  G. Sczakiel,et al.  Ki-67-directed antisense therapy in an orthotopic renal cell carcinoma model. , 2004, European urology.

[43]  S. Horvath,et al.  Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. , 2004, The Journal of urology.

[44]  M. Tsai,et al.  Structure of human Ki67 FHA domain and its binding to a phosphoprotein fragment from hNIFK reveal unique recognition sites and new views to the structural basis of FHA domain functions. , 2004, Journal of molecular biology.

[45]  T. Cheutin,et al.  Three-dimensional Organization of pKi-67: A Comparative Fluorescence and Electron Tomography Study Using Fluoronanogold , 2003, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[46]  S. Horvath,et al.  Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. , 2003, Urology.

[47]  H. Pandha,et al.  Renal-cell carcinoma: tumour markers, T-cell epitopes, and potential for new therapies. , 2003, The Lancet. Oncology.

[48]  A. Böhle,et al.  Antisense oligonucleotide therapy in urology. , 2002, The Journal of urology.

[49]  J. Gerdes,et al.  The Ki‐67 protein interacts with members of the heterochromatin protein 1 (HP1) family: a potential role in the regulation of higher‐order chromatin structure , 2002, The Journal of pathology.

[50]  Y. Yoneda,et al.  A Novel Nucleolar Protein, NIFK, Interacts with the Forkhead Associated Domain of Ki-67 Antigen in Mitosis* , 2001, The Journal of Biological Chemistry.

[51]  W. Gerald,et al.  Alterations of cell cycle regulators affecting the RB pathway in nonfamilial retinoblastoma. , 2001, Human pathology.

[52]  Y. Yoneda,et al.  The Forkhead-associated Domain of Ki-67 Antigen Interacts with the Novel Kinesin-like Protein Hklp2* , 2000, The Journal of Biological Chemistry.

[53]  N. Rioux-Leclercq,et al.  Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. , 2000, Urology.

[54]  J. Gerdes,et al.  Posttranslational modifications of the KI‐67 protein coincide with two major checkpoints during mitosis , 2000, Journal of cellular physiology.

[55]  Christian A. Rees,et al.  Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[56]  M. Takagi,et al.  Chmadrin: a novel Ki-67 antigen-related perichromosomal protein possibly implicated in higher order chromatin structure. , 1999, Journal of cell science.

[57]  M. Weil,et al.  MPM‐2 epitope sequence is not sufficient for recognition and phosphorylation by ME kinase‐H , 1997, FEBS letters.

[58]  I. Kill.  Localisation of the Ki-67 antigen within the nucleolus. Evidence for a fibrillarin-deficient region of the dense fibrillar component. , 1996, Journal of cell science.

[59]  D. Corey,et al.  Inhibition of human telomerase activity by peptide nucleic acids , 1996, Nature Biotechnology.

[60]  B. Delahunt,et al.  Proliferation of renal cell carcinoma assessed by fixation‐resistant polyclonal Ki‐67 antibody labeling. Correlation with clinical outcome , 1995, Cancer.

[61]  M. Kirschner,et al.  A 20s complex containing CDC27 and CDC16 catalyzes the mitosis-specific conjugation of ubiquitin to cyclin B , 1995, Cell.

[62]  S. Osmani,et al.  The NIMA protein kinase is hyperphosphorylated and activated downstream of p34cdc2/cyclin B: coordination of two mitosis promoting kinases. , 1995, The EMBO journal.

[63]  D. Hernandez-Verdun,et al.  The chromosome periphery during mitosis , 1994, BioEssays : news and reviews in molecular, cellular and developmental biology.

[64]  J. Kuang,et al.  cdc25 is one of the MPM-2 antigens involved in the activation of maturation-promoting factor. , 1994, Molecular biology of the cell.

[65]  J. Gerdes,et al.  The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins , 1993, The Journal of cell biology.

[66]  G. Gorbsky,et al.  DNA topoisomerase II alpha is the major chromosome protein recognized by the mitotic phosphoprotein antibody MPM-2. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[67]  S. Bruno,et al.  Cell cycle dependent expression and stability of the nuclear protein detected by Ki‐67 antibody in HL‐60 cells , 1992, Cell proliferation.

[68]  J. Gerdes,et al.  Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. , 1991, The American journal of pathology.

[69]  G. Maul,et al.  A nucleolar auto-antigen is part of a major chromosomal surface component , 1990, Chromosoma.

[70]  H Stein,et al.  Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. , 1984, Journal of immunology.

[71]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[72]  A. Gorelov,et al.  [Prognostic value of ki-67 and vimentin markers in patients with metastatic kidney cancer]. , 2014, Urologiia.

[73]  M. Huang,et al.  Short hairpin RNA (shRNA): design, delivery, and assessment of gene knockdown. , 2010, Methods in molecular biology.

[74]  A. Tabatabaei,et al.  IMMUNOHISTOCHEMICAL EXPRESSION OF P53 PROTEIN IN HISTOLOGICALLY FAVORABLE WILMS TUMOR AND ITS RELATIONSHIP TO TUMOR STAGE AT PRESENTATION , 2006 .

[75]  Jason R Swedlow,et al.  Time-lapse imaging reveals dynamic relocalization of PP1gamma throughout the mammalian cell cycle. , 2003, Molecular biology of the cell.

[76]  T. Coleman,et al.  Cell cycle regulation of a Xenopus Wee1-like kinase. , 1995, Molecular biology of the cell.

[77]  R. van Driel,et al.  Ki-67 detects a nuclear matrix-associated proliferation-related antigen. I. Intracellular localization during interphase. , 1989, Journal of cell science.